[This article was published in the November 2008 issue of the eHEALTH Magazine (https://www.ehealthonline.org)]
For the business news updates of the health care industry for the month of November 2008, browse through the pages of eHealth.
Nicholas Piramal (NPIL) has reportedly signed a research deal potentially worth a maximum revenue of USD 350 million with US pharmaceutical giant Merck & Co to carry out early discovery and development of two new cancer drugs, the two companies said on Monday.
